Dr Bruce Roser

Chairman and Founder

Bruce founded Stablepharma in 2012 in order to bring to the market his important work on vaccine stabilisation. Over his career as a physician and scientist he published 108 papers and 49 Patents. He is a recognised world authority in drug stabilisation and delivery and was nominated for the ‘Great Britons of 2004’ awards for his work on stabilisation technology. In 1985 he patented the remarkable stabilizing activity of trehalose glasses on vaccines and other biologicals. In 1996 he set up the Anglia Research Foundation at Anglia Ruskin University. in Cambridge and subsequently founded Cambridge Biostability Ltd. He worked as Director and Chief Scientific Adviser in its Cambridge Laboratories to develop and exploit new discoveries in the stabilization and delivery of drugs and vaccines.

Nick Child

Managing Director and Founder

Nick is an experienced company director/leader across multiple disciplines with many years of experience in UK and International markets. Over his career he has initiated various start-ups and has significant experience of acquisitions, and funding rounds. He specialises in the identification of new or developing markets and exploits new and sometimes disruptive technological advances. Nick has a history of brand creation and development with strong marketing and PR support. He is a strategic and rational planner with an experience-based problem solving skillset.

Dr Arcadio García de Castro

Head of Research and Development

Arcadio has a BSc in Microbiology and PhD in biotechnology from the University of Surrey. Prior to joining Stablepharma he was R&D Director and along with Bruce was co-founder of Cambridge Biostability Ltd. (UK), and a researcher at the Univ. of Cambridge. Additionally, Arcadio was the founder and CEO of AzureBio S.L (Spain) for ten years and President of the board of S2B Technology Park. He has held senior scientific Business Development positions at Chimera Pharma S.L (Spain), OncoStem Pharma (Spain) and PharmaMar-Zeltia (Spain). He has long specialised in drug and vaccine stabilization and delivery technologies and has a strong interest is the broader field of Medical Devices and biomaterials. He is the author of over 20 patents in drug and vaccine formulation and delivery.    

Martin Powell

Legal Council and Director

Martin is an experienced legal practice Managing Partner with a passion for business success and growth. With several industry awards under his belt (including Legal Business Awards 2007 - "Most Enterprising Law Firm"), he left Withy King in 2011 to create Omnialegal Limited in 2012. 

Neil Mayall

Financial Director

Neil has over 23 years of experience as a consultant and consulting practice leader within the Financial Services industry. He was a founder and Finance director of Troika (UK) Ltd, arranging the sale of that business to Navigant in 2007. He co-founded Pen Partnership Ltd in 2012. Neil specialises in the planning and implementation of large scale change programmes and business turn around. 

Özgür Tuncer

Strategy Director

Özgür is a strategic advisor to healthcare investors and the life sciences industry, expert in corporate strategy, M&A, new product development and global portfolio management. He is currently a Vice President at IQVIA Consulting Services, member of the Global Leadership Team (GLT) and global leader for IQVIA’s Financial Institutions Consulting (FIC). He spent over 6 years working for Pfizer in New York and Pharmacia in New Jersey before moving into management consultancy. Prior to joining IMS Health (IQVIA), Özgür was the founding Managing Partner of SARGA Associates with offices in New Jersey, USA and London, UK. He has also worked with several NGOs at the CEO level, including Medicines for Malaria Venture in Geneva, UNITAID, Clinton Foundation/Clinton Health Access Initiative and the Gates Foundation. He holds an MSc in Management Sciences from the London School of Economics and a BSc in Business Admininstration from the Middle East Technical University (Turkey).

Charlie Goddard

Operations Director

A result focused senior advisor and consultant with 20+ years’ experience in the financial services industry and start up communities. Charlie’s deep expertise and understanding of the complexity of change, business growth and specialism in all aspects of outsourcing is a great addition to the Board of Stablepharma.

As an integral part of the Board of Stablepharma, Charlie is well positioned to drive the development of the company’s corporate strategy and flow of operations information to ensure key objectives are met and delivered and all necessary policies and procedures are in place.

Prof. Alan Boyd

Regulatory Advisor

Alan is the current president of the Faculty of Pharmaceutical medicine (UK) with over 30 years’ experience in pharmaceutical industry with track record to bringing medical developments to the market. Former head of Medical Research for Zeneca Pharmaceuticals.

Laura Murphy

Marketing & Communications Advisor

Laura is a founding director of Fusebox Communications Ltd. Senior marketing and Communications executive with experience in big pharma product launch communications.

Gunther Faber

Advisory Board

Gunther retired as Vice President Sub-Saharan Africa for Glaxo SmithKline in 2008. During his time there he was accountable for pharmaceuticals, vaccines consumer health and manufacturing. He also also led the company’s Policy Team on Access to Medicine, as well as being a director of the International Division which covered all countries with the exception of the USA, Europe and Japan. He is the founder and Chairman of One Family Health, an NGO providing access to essential medicines and basic healthcare services to isolated communities in Africa. 

Mike Bellis

Advisory Board

Mike is a Certified Customer Experience Professional and heads up the Pharmaceutical Consulting division of PEN Partnership Limited. He has over 20 years of experience working in the pharmaceutical industry in senior commercial roles. During his time in industry he specialised in the commercialisation of pharma products bringing new products to market across many geographies, including the launch and management of small (tens of $m) and large (over $1Bn) products for the top 4 pharma companies.